images (2)

trenbolone 250

Is subjected to enzymatic digestion by alpha-amylase blood, which leads to the formation of oligo- and polysaccharides of various molecular weights.  Has a  from the blood of about 4 hours.Write trenbolone 250 mainly via the kidneys; 50% of the administered dose is excreted in the urine in less than 24 hours. Small amounts of drug deposited in the tissues temporarily, only 10% and continues to circulate in the blood serum. Sodium chloride is excreted mainly by the kidneys, and a small amount is excreted in the later through the skin.


1 .Lechenie and hypovolemia and shock prevention when:

  • surgery (hemorrhagic shock)
  • traumatic lesions (traumatic shock)
  • infections (septic shock)
  • burns (burn shock).

2.Ostraya normovolemic hemodilution to reduce the introduction of donor blood during surgery.

3 .Terapevticheskaya trenbolone 250 hemodilution.


Hypersensitivity (including starch), intracranial hypertension, arterial hypertension, intracranial hemorrhage, decompensated chronic heart failure, acute renal failure (oligo, anuria), severe bleeding diathesis, cardiogenic pulmonary edema, anticoagulation, coagulopathy, hyperhydration, hypervolemia, dehydration (if necessary correction of electrolyte metabolism), gipofibrinogenemia, severe thrombocytopenia, giperiatriemiya, hemodialysis.

Precautions: during lactation, compensated chronic heart failure, chronic renal failure, chronic liver disease, von Willebrand disease, hemorrhagic diathesis.

Use during pregnancy and lactation

Data on the use of trenbolone 250 in pregnant and lactating women do not. Use of the drug during pregnancy and lactation is possible only for health reasons.

Dosing and Administration


Dosages employed for the treatment and prevention of hypovolemia and shock.

The maximum daily dose:

6% solution 33 ml / kg / day (= 2,500 ml per 75 kg of body weight per day, or HEC = 2 g / kg / day).

10% solution 20 ml / kg / day (= 1,500 ml per 75 kg of body weight per day, or HEC = 2 g / kg / day).

Maximum infusion rate:

6% solution 20 ml / kg / hour (= 1500 ml per 75 kg of body weight per hour or 1,2 g HES / kg / hour).

10% solution 20 ml / kg / hour (= 1500 ml per 75 kg of body weight per hour or HES 2 g / kg / hour).

The doses used to reduce the amount of blood during surgery (acute normovolemic hemodilution).

For immediate preoperative substitution of his own blood to the simultaneous introduction of Hayes sr 6% in the ratio of 1: 1 (up to hematocrit

not less than 30%).

Sampling blood: 3.2 ml of 500 fold of their own blood.

Daily dose: 2-3 infusion of 500 mL of sterile-Hayes 6%.

Blood sampling trenbolone 250 rate of 1000 ml in 15-30 minutes.

images (3)

trenbolone mix genesis

Patients suffering from hemophilia . persons who have household contact with an infectedviral shedding can occur for quite a long time. Therefore trenbolone mix genesis is recommended for all persons who are in contact with an infected person. The populations with known high incidence of hepatitis A or those populations in which the incidence of hepatitis A is increased due to low hygienic conditions. Persons with chronic liver disease or an increased risk of liver disease (chronic carriers of  delta, people with chronic hepatitis alcoholic, autoimmune, toxic, drug and other origin, a person with Wilson’s disease, steatosis, and hepatopathy). In areas of moderate or high endemicity vaccination against hepatitis A is recommended for all susceptible populations. Introduction on the background of the flowing of hepatitis A in the incubation period does not worsen the disease. Can be administered to HIV-infected patients. The presence of antibodies to hepatitis A virus after the first vaccination is not a contraindication to revaccination .


Effects on ability to ability to concentrate
is unlikely trenbolone mix genesis.

Product Form
In 0.5 ml or 1 ml of a clear colorless glass vial type! USP capacity of 2 ml or 3 ml, sealed with rubber stopper and aluminum cap under run-provided with a protective plastic cover.
In 0.5 ml capacity disposable syringe 1.5 ml borosilicate glass type I PSP needle 25G5 / 8 Stainless Steel type 304 polypropylene and a piston provided with a rubber protective cap covering the needle.
with a 1.0 ml capacity disposable syringe 1.5 ml borosilicate glass type I USP 23G1 needle of stainless steel type 304 polypropylene piston and provided with a protective cap of rubber covering the needle.
Before 1 bottle in paper cartons, 10, 25 and 100 bottles in a cardboard box with the corresponding number trenbolone mix genesis of instructions for medical use.
on 1 syringe in a plastic blister pack in a carton together with instructions for medical use.


trenbolone mix

The vaccine trenbolone mix can be administered concurrently with inactivated vaccines in the national calendar of preventive RF vaccination and immunization schedule for epidemic RF indications.
Because the vaccine  is inactivated, it is unlikely that its simultaneous administration with other inactivated vaccines will lead to disruption of the immune response. Simultaneous administration of inactivated vaccines against typhoid fever, cholera, tetanus, as well as yellow fever, reduced the immune response was not observed.
When administered simultaneously with human immunoglobulins protective effect of the vaccine is not reduced.
If it is necessary to introduce  from other vaccines or immunoglobulins, the preparations are administered using different syringes and needles in the various parts of the body.

Side effects
The vaccine trenbolone mix is generally well tolerated. Perhaps the development of local reactions: transient soreness at the injection site (assessed as severe in less than 0.5% of cases); redness and swelling, the frequency of which was about 4% of the total number of vaccination.
The general reaction relate primarily to the weak, and the duration of most of them did not exceed 24 hours. Common reactions are headache, malaise, vomiting, fever, nausea and loss of appetite .Frequency of these events ranged from 0.8% to 12.8% of the total number of vaccinations. All of these adverse events resolved without sequelae.
The nature and symptoms of adverse reactions in children was the same as in adults, but they have adverse reactions were observed less frequently. During the post-registration of observations noted in rare cases, such phenomena as fatigue, diarrhea, myalgia, arthralgia, allergic reactions, including anafidaktoidnye reaction, as well as seizures.

So far, cases of overdosage have been reported.

Pregnancy and lactation
B due to the lack of adequate data on the use of the vaccine during pregnancy and lactation, enter  pregnant and lactating women is not recommended, despite the minimal risk of exposure to inactivated vaccine on the fetus and child.
Pregnancy and lactation should be used only if the absolute indications.

Special instructions:
In areas with low to moderate endemicity of hepatitis A ymmunizatsiya vaccine “Havrix” is highly recommended for individuals at increased risk of infection, as well as persons who have hepatitis A can have a severe course or persons whom hepatitis A because of their professional affiliation can cause explosions. These include: Travellers: persons traveling in hyperendemic regions or in regions where trenbolone mix registered vspyschechnaya incidence of hepatitis A. The military: officers of military units stationed in areas with poor sanitation or non-guaranteed water supply. Those diseases which hepatitis A because of their professional accessories can cause outbreaks, and for which there is a professional risk of exposure to hepatitis A virus: the employees of schools and kindergartens, middle and junior medical staff, especially in infectious gastroenterology and pediatric health care facilities, workers sewerage systems and water treatment plants, employees of enterprises catering, food industry, food warehouses, staff of closed MDPA agencies, social security and health care. Persons residing or staying in the outbreak of hepatitis a , including, family, or living in areas where vspyschechnaya incidence recorded. Persons with risk behaviors infection with hepatitis a virus: .